Harold Aubrey de Lavenu - Jul 12, 2017 Form 3/A - Amendment Insider Report for CEN BIOTECH INC (CENBF)

Role
Director
Signature
/s/ Harold Aubrey de Lavenu
Stock symbol
CENBF
Transactions as of
Jul 12, 2017
Transactions value $
$0
Form type
3/A - Amendment
Date filed
5/28/2021, 08:30 AM
Date Of Original Report
Apr 22, 2021
Next filing
May 28, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CENBF Common Stock 13.3K Jul 12, 2017 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CENBF Convertible Note Jul 12, 2017 Common Stock 62.5K $1.60 Direct F2, F3
holding CENBF Convertible Note Jul 12, 2017 Common Stock 125K $1.60 Direct F2, F3
holding CENBF Convertible Note Jul 12, 2017 Common Stock 156K $1.60 Direct F2, F3
holding CENBF Convertible Note Jul 12, 2017 Common Stock 313K $1.60 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Harold Aubrey de Lavenu (the "Reporting Person") was appointed to his position with CEN Biotech, Inc. (the "Issuer") on July 12, 2017 and owned 13,321 shares of the Issuer's common stock on such date. On April 2, 2021, the Issuer appointed the Reporting Person to serve as a Vice President of the Issuer effective as of April 2, 2021
F2 Additionally the Reporting Person owned convertible notes on July 12, 2017, which the Reporting Person purchased from the Issuer which were at such time and still are convertible into 656,250 shares of the Issuer's common stock.
F3 The convertible notes included in this table matured on May 12, 2018, November 25, 2018, December 14, 2018, and February 19, 2019, respectively, (the "Maturity Dates"), however, the ability to convert the notes into shares did not expire on the Maturity Dates of the notes.